维普期刊资源整合服务平台（V6.5）

194篇 您的检索式：作者名="Burstein HJ"

选中清除导出查看参考文献查看引证文献引用追踪共10页首页上一页第1页下一页末页 /10 跳转

	题名	作者	年代	出处	被引量
1	Randoumized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-postivie, trastu- zumab-refractory metastatic breast cancer 显示文摘	Blackwell KL Burstein HJ Storniolo AM	2010	J Clin Oncol2010，28，7：	1
2	Novel agents and future directions for refractorybreast cancer显示文摘	BURSTEIN HJ	2011	Semin Oncol f2011，，：	1
3	Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive,trastuzumab-refractory metastatic breast cancer显示文摘	Blackwell KL Burstein HJ Storniolo AM	2010	Clin Oncol2010，28，7：	1
4	Neratinib,an irreversible ErbB receptor tyrosine kinase inhibitor,in patients with advanced ErbB2-positive breast cancer 显示文摘	Burstein HJ Sun Y Dirix LY	2010	J Clin Oncol2010，28，8：	1
5	The distinctive nature of her - 2 positive breast cancer 显示文摘	Burstein HJ	2005	N Eng J Meal2005，353，16：	1
6	American society of clinical oncology technology assessment on the use of aromotase inhibitors as adjuvant theraphy for postmenopausal women with hormone receptor-positive breast cancer:status report 2004显示文摘	Winer EP Hudis C Burstein HJ	2005	J Clin Oncol2005，23，3：	1
7	Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2- positive, trastuzumab- refractory metastatic breast cancer显示文摘	BLACKWELL KL BURSTEIN HJ STORNIOLO AM et ol	2010	J Clin Oncol2010，28，7：	1
8	Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage Ⅱ or Ⅲ breast cancer a pilot study显示文摘	Burstein HJ Harris LN Gelman R	2003	J Clin Oncol2003，21，：	1
9	CentSral nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast earcinoma显示文摘	Bendell JC Domchek SM Burstein HJ	2003	Caneer2003，97，：	1
10	American society of clinic-oncology technology assessment on the use of aromotasein hibitors as adjuvant theraphy for postmenopausal women with hormone receptor-positive breast cancer status report显示文摘	Winer EP Hudis C Burstein HJ	2005	ClinOncol2005，23，3：	1
11	American society of clinical oncology clinical practice guideline: update on adjuvant en- docrine therapy for women with hormone receptor-positive breast cancer显示文摘	Burstein HJ Prestrud AA Seiden- feld J	2010	J Clin Oncol2010，28，23：	1
12	Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease显示文摘	Gralow JR BurStein HJ Wood W	2008	J Clin Oncol2008，26，5：	1
13	Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study显示文摘	Blackwell KL Burstein HJ Storniolo AM	2012	J Clin On- col2012，30，21：	1
14	American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer:Status report 2004显示文摘	Winer EP Hudis C Burstein HJ	2005	J Clin Oncol2005，23，3：	1
15	Ductal carcinoma in situ of the breast显示文摘	Burstein HJ Ployak K Wong JS	2004	N Engl J Med2004，305，14：	1
16	Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer:A phase Ⅱ study显示文摘	Burstein HJ Demetri GD Mueller E	2003	Breast Cancer Res Treat2003，79，3：	1
17	The role of angiogenesis inhibition in the treatment of breast cancer显示文摘	Sledge GW Rugo HS Burstein HJ	2006	Clin Adv Hematol Oncol2006，21，10：	1
18	VEGF as marker for outcome among advanced breast cancer patients receiving antiVEGF therapy with bevacizumab and vinorelbine chemotherapy显示文摘	Burstein HJ Chen YH Parker LM	2008	Clin Cancer res2008，14，23：	1
19	Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2- positive breast cancer显示文摘	BURSTEIN HJ SUN Y DIRIX LY	2010	J Clin Oneol2010，28，8：	1
20	Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory Metastatic breast cancer显示文摘	Blackwell KL Burstein HJ Storniolo AM	2010	J Clin Oncol2010，28，7：	1

返回顶部每页显示：

共10页首页上一页第1页下一页末页 /10 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示